小剂量利妥昔单抗在难治性免疫性血小板减少症中的应用  

Application of low-dose rituximab in refractory immune thrombocytopenia

作　　者：罗毅[1] 张文丽[1] 邓小雅 钟丽文 

机构地区：[1]广东省廉江市人民医院,广东廉江524400

出　　处：《广东医学院学报》2015年第3期360-362,共3页Journal of Guangdong Medical College

摘　　要：目的观察小剂量利妥昔单抗治疗难治性免疫性血小板减少症(ITP)的临床疗效。方法 14例难治性ITP患者用小剂量利妥昔单抗治疗,观察治疗后血小板计数及不良反应。结果治疗后第4、6、12周的血小板计数明显高于治疗前(P<0.01),12周时有效率为71.4%。5例出现静脉输注相关事件,包括心悸2例,一过性头痛、发热、恶心、呕吐各1例。结论小剂量利妥昔单抗是难治性ITP安全、有效疗法。Objective To observe the clinical efficacy of low-dose rituximab in refractory immune thrombocytopenia（ITP）. Methods Fourteen patients with refractory ITP were treated with low-dose rituximab. The platelet counts and adverse reactions were observed. Results The platelet counts at 4, 6 and 12 weeks after treatment were significantly higher than those before treatment（P〈0.01）. The effective rate was 71.4% at 12 weeks. The intravenous infusion-related events occurred in 5 cases, including palpitation（2）, transient headache（1）, fever（1）, nausea（1）, and vomit（1）. Conclusion Low-dose rituximab is safe and effective for refractory ITP.

关 键 词：免疫性血小板减少症 利妥昔单抗 血小板 

分 类 号：R446.1[医药卫生—诊断学]